Long-term omalizumab treatment in severe allergic asthma: The South-Eastern Mediterranean “real-life” experience

Abstract Background Omalizumab is a recombinant humanized anti-IgE monoclonal antibody indicated as an add-on treatment for severe allergic asthma, inadequately controlled despite high dose of inhaled corticosteroids (ICS) and long-acting b2-agonists. Objectives Medical registries were used to evalu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pulmonary pharmacology & therapeutics 2012-02, Vol.25 (1), p.77-82
Hauptverfasser:	Tzortzaki, Eleni G, Georgiou, Andreas, Kampas, Dimitrios, Lemessios, Marinos, Markatos, Miltiadis, Adamidi, Tonia, Samara, Katerina, Skoula, Georgia, Damianaki, Aggeliki, Schiza, Sophia, Tzanakis, Nikos, Siafakas, Nikolaos M
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Inhalation Adrenal Cortex Hormones - administration & dosage Adrenal Cortex Hormones - therapeutic use Aged Allergy Anti-Asthmatic Agents - administration & dosage Anti-Asthmatic Agents - adverse effects Anti-Asthmatic Agents - therapeutic use Anti-IgE Antibodies, Anti-Idiotypic - administration & dosage Antibodies, Anti-Idiotypic - adverse effects Antibodies, Anti-Idiotypic - therapeutic use Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Asthma Asthma - complications Asthma - drug therapy Asthma - etiology Cohort Studies Data Collection Drug Therapy, Combination Efficacy Female Forced Expiratory Volume Humans Hypersensitivity - complications Immunoglobulin E Long-Term Care Male Medical Education Mediterranean Region Middle Aged Omalizumab Pulmonary/Respiratory Severe asthma Spirometry Therapy Treatment Outcome Vital Capacity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!